Payment overview · 2025
General Payments
$410.52
21 reported records · 10 companies
Healthcare provider profile · identity verified
Ibrahim Bshara, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, OH · NPI 1740256445
Verified facts
What the public records show
CMS Open Payments records show Ibrahim Bshara, MD received $410.52 in general payments during 2025 across 21 reported records.
Alnylam Pharmaceuticals Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.90 | 23.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $69.86 | 17.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.83 | 13.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.15 | 12.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.47 | 12.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.22 | 5.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.20 | 4.9% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.45 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.89 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.55 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $410.52 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $94.90 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $69.86 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.83 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
121 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 856 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 645 | 120 |
| Lisinopril | Lisinopril | 476 | 84 |
| Eliquis | Apixaban | 396 | 64 |
| Metformin Hcl | Metformin Hcl | 363 | 86 |
| Gabapentin | Gabapentin | 344 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 303 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 71 |
| Furosemide | Furosemide | 231 | 69 |
| Enalapril Maleate | Enalapril Maleate | 217 | 40 |
| Meloxicam | Meloxicam | 211 | 58 |
| Carvedilol | Carvedilol | 208 | 37 |
| Omeprazole | Omeprazole | 202 | 41 |
| Simvastatin | Simvastatin | 200 | 46 |
| Jardiance | Empagliflozin | 175 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 166 | 42 |
| Donepezil Hcl | Donepezil Hcl | 165 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 33 |
| Potassium Chloride | Potassium Chloride | 147 | 44 |
| Sertraline Hcl | Sertraline Hcl | 138 | 32 |
| Trazodone Hcl | Trazodone Hcl | 136 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 28 |
| Mirtazapine | Mirtazapine | 123 | 30 |
| Xarelto | Rivaroxaban | 121 | 15 |
| Losartan Potassium | Losartan Potassium | 119 | 29 |
| Allopurinol | Allopurinol | 110 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 21 |
| Memantine Hcl | Memantine Hcl | 89 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 19 |
| Risperidone | Risperidone | 80 | 11 |
| Spironolactone | Spironolactone | 80 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 78 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 22 |
| Midodrine Hcl | Midodrine Hcl | 64 | 20 |
| Torsemide | Torsemide | 62 | 25 |
| Warfarin Sodium | Warfarin Sodium | 62 | 13 |
| Azithromycin | Azithromycin | 61 | 42 |
| Levetiracetam | Levetiracetam | 61 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 13 |
| Latanoprost | Latanoprost | 60 | 17 |
| Ibuprofen | Ibuprofen | 56 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 24 |
| Divalproex Sodium | Divalproex Sodium | 53 | 18 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Famotidine | Famotidine | 52 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 11 |
| Montelukast Sodium | Montelukast Sodium | 48 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 33 |
| Clozapine | Clozapine | 47 | suppressed |
| Lactulose | Lactulose | 46 | suppressed |
| Brilinta | Ticagrelor | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Finasteride | Finasteride | 42 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | 13 |
| Cephalexin | Cephalexin | 41 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 27 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 13 |
| Ozempic | Semaglutide | 40 | 13 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Glipizide | Glipizide | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 36 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 21 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Nystatin | Nystatin | 34 | 15 |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Dexamethasone | Dexamethasone | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 20 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Prednisone | Prednisone | 30 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 20 |
| Naproxen | Naproxen | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | 15 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 26 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 22 | 12 |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Loxapine | Loxapine Succinate | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $410.52 · 21 records | Alnylam Pharmaceuticals Inc. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, FUROSCIX, MOUNJARO, ONPATTRO, OTEZLA, Ozempic, REPATHA, SPRAVATO, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error